CoChat

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Abstract

The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.

Overview

Integrity signals

Registry

Crossref · 10.1021/jm101459g

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 3

  1. Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
  2. Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
  3. Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page

Cited by

Items 301–400 of 628

Metadata

Authors
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
Affiliations
  • Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
  • Lundbeck (Denmark) (DK)
  • Lundbeck (United States) (US)
Venue
Journal of Medicinal Chemistry
Published
2011-04-12
Volume
54
Issue
9
Pages
3206-3221
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2036812642
Cited by
606
References
58
Citations by year
2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
FWCI
21.08
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
MeSH terms
Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.